Shaun Rezaei

Title: Shaun Rezaei: Innovator in Antidepressant Detection

Introduction

Shaun Rezaei is a notable inventor based in Santa Clarita, CA (US). He has made significant contributions to the field of mass spectrometry, particularly in the detection of antidepressants. His innovative approach has the potential to enhance the accuracy of antidepressant measurements in clinical settings.

Latest Patents

Shaun Rezaei holds a patent for a method titled "Determination of antidepressants by mass spectrometry." This patent describes a technique for detecting or determining the amount of serotonin and norepinephrine reuptake inhibitors (SNRIs) and their metabolites in a sample using tandem mass spectrometry. The method involves ionizing the sample under specific conditions to produce detectable ions, followed by quantifying these ions to ascertain the levels of SNRIs and their metabolites, including duloxetine. He has 1 patent to his name.

Career Highlights

Rezaei is currently associated with Quest Diagnostics Investments, Inc., where he applies his expertise in mass spectrometry to advance diagnostic methods. His work is pivotal in improving the understanding and measurement of antidepressant levels in patients.

Collaborations

Some of his coworkers include Anita Dermartirosian and Edith Shahbol, who contribute to the collaborative environment at Quest Diagnostics Investments, Inc. Their combined efforts enhance the research and development of innovative diagnostic solutions.

Conclusion

Shaun Rezaei's contributions to the field of antidepressant detection through mass spectrometry exemplify the impact of innovation in healthcare. His work not only advances scientific understanding but also has practical implications for patient care.